Dataset Information
Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.
Ontology highlight
ABSTRACT: Introduction
We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients.Methods
Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, body mass index (BMI) ≥ 25 kg/m(2). The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage.Results
There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin.Conclusion
Despite no proliferation changes, we observed reductions in other relevant biomarkers.
SUBMITTER: Kalinsky K
PROVIDER: S-EPMC4435671 | biostudies-literature | 2014 May
REPOSITORIES: biostudies-literature
Publications
Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.
Cancer investigation 20140307 4
<h4>Introduction</h4>We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients.<h4>Methods</h4>Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, body mass index (BMI) ≥ 25 kg/m(2). The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage.<h4>Results</h4>There was no reduction in ...[more]
